Home

Richard W Pascoe

CIK 1343266 · Chief Executive Officer · last filed 2024-01-08

Richard W Pascoe is a Chief Executive Officer who has filed 65 SEC Form 4 insider transactions across 7 companies since 2007. The most recent filing, for SEEL, was dated Jan 8, 2024. Across all open-market trades the lifetime net is −$703.6K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $371.7K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$371.7K

Companies

7

Total Filings

65

Lifetime Open-Market Net

-$703.6K

Filer Profile

Reported Address
C/O SEELOS THERAPEUTICS, INC.
300 PARK AVENUE, 12TH FLOOR
NEW YORK, NY 10022
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
SEELOS THERAPEUTICS, INC. (SEEL) Delisted Director 40 $0.39 $16 $0 7 2024-01-08
ZVRA Chief Executive Officer 29,973 $12.40 $371.7K $42.0K 1 2023-03-13
ZEVRA THERAPEUTICS, INC. (KMPH) Delisted Chief Executive Officer 19,973 $5.81 $116.0K $94.5K 16 2023-01-13
Histogen Inc. (HSTO) Delisted President, CEO & Director 1,500 $0.21 $322 $35.2K 4 2021-03-30
SEELOS THERAPEUTICS, INC. (APRI) Delisted CEO & Secretary 6,674 — — $128.1K 14 2018-11-30
Pernix Sleep, Inc. (SOMX) Delisted President and CEO 104,927 — — -$1.00M 19 2013-01-03
ARIAD PHARMACEUTICALS INC (ARIA) Delisted Senior VP, COO — — — $0 3 2008-04-15

Recent Filings

65 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-01-08 SEELOS THERAPEUTICS, INC. (SEEL) Delisted Grant (A) — $0 EDGAR
2023-03-13 ZVRA Buy (P) +10,000 $42.0K EDGAR
2023-01-13 ZEVRA THERAPEUTICS, INC. (KMPH) Delisted Buy (P) +9,500 $51.7K EDGAR
2023-01-11 ZEVRA THERAPEUTICS, INC. (KMPH) Delisted Grant (A) — $0 EDGAR
2023-01-05 SEELOS THERAPEUTICS, INC. (SEEL) Delisted Grant (A) — $0 EDGAR
2022-05-18 ZEVRA THERAPEUTICS, INC. (KMPH) Delisted Buy (P) +5,000 $24.6K EDGAR
2022-02-03 ZEVRA THERAPEUTICS, INC. (KMPH) Delisted Grant (A) — $0 EDGAR
2022-01-06 SEELOS THERAPEUTICS, INC. (SEEL) Delisted Grant (A) — $0 EDGAR
2021-11-30 ZEVRA THERAPEUTICS, INC. (KMPH) Delisted Buy (P) +1,500 $11.8K EDGAR
2021-11-10 ZEVRA THERAPEUTICS, INC. (KMPH) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 65
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.